News

The experimental immunotherapy IGV-001 may improve survival outcomes in certain people with an aggressive form of glioma called glioblastoma (GBM), according to a new…

The U.S. Food and Drug Administration (FDA) has given GT Biopharma a green light to start a Phase…

Inflammation plays a key role in the progression of polycythemia vera (PV), making it an important potential treatment target. In a new Perspective article,…

Artificial intelligence (AI) may help design better CAR T-cell therapies to treat myeloma and other cancers, a study showed. An AI-designed CAR…

The U.S. Food and Drug Administration (FDA) has awarded its breakthrough therapy designation — which aims to speed the development of promising new medications —…

Treatment with Tecvayli (teclistamab), an approved cancer drug, can reduce the risk of disease progression in people with high-risk smoldering multiple myeloma, an…

The overall risk of any infection in the first year after starting treatment is similar in people given different types of immune-modulating therapies for…

Bristol Myers Squibb‘s experimental cell therapy arlocabtagene autoleucel (arlo-cel) may help control myeloma that has returned or failed…

A CAR T-cell therapy targeting glioblastoma improved tumor control and survival in mice when given before surgery rather than afterward, according to a new study.

September is Gynecologic Cancer Awareness Month, and advocacy groups are running campaigns to raise awareness about gynecological cancers, raise funds for research, and…